|
JP2884452B2
(ja)
|
1991-10-09 |
1999-04-19 |
清水建設株式会社 |
セグメントを利用した立坑構築工法
|
|
CA2635581C
(en)
|
2005-12-28 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
DK2240451T3
(da)
|
2008-01-04 |
2017-11-20 |
Intellikine Llc |
Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
|
|
AU2009288088B2
(en)
|
2008-09-03 |
2014-12-04 |
Nono Inc. |
Agents and methods for treatment of pain
|
|
AU2010327936B2
(en)
*
|
2009-12-11 |
2015-08-20 |
Nono Inc. |
Agents and methods for treating ischemic and other diseases
|
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
AU2011202542A1
(en)
*
|
2010-07-14 |
2012-02-02 |
Indian Institute Of Science |
Benzothiophene carboxamide compounds, composition and applications thereof
|
|
CR20180412A
(es)
|
2010-07-16 |
2018-11-01 |
Abbvie Ireland Unlimited Co |
Proceso para preparar compuestos antivirales
|
|
US9255074B2
(en)
|
2010-07-16 |
2016-02-09 |
Abbvie Inc. |
Process for preparing antiviral compounds
|
|
US8975443B2
(en)
|
2010-07-16 |
2015-03-10 |
Abbvie Inc. |
Phosphine ligands for catalytic reactions
|
|
US8841487B2
(en)
|
2010-07-16 |
2014-09-23 |
Abbvie Inc. |
Phosphine ligands for catalytic reactions
|
|
BR112013011188B1
(pt)
|
2010-11-05 |
2022-01-04 |
Senomyx, Inc |
Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto
|
|
US8980924B2
(en)
|
2010-11-24 |
2015-03-17 |
The Trustees Of Columbia University In The City Of New York |
Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
|
|
DK2663309T3
(en)
|
2011-01-10 |
2017-06-19 |
Infinity Pharmaceuticals Inc |
METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
|
|
CA2839438C
(en)
|
2011-06-15 |
2020-08-04 |
Nono Inc. |
Agents and methods for treating ischemic and other diseases
|
|
KR20140063605A
(ko)
|
2011-07-19 |
2014-05-27 |
인피니티 파마슈티칼스, 인코포레이티드 |
헤테로사이클릭 화합물 및 그의 용도
|
|
KR20130016041A
(ko)
*
|
2011-08-04 |
2013-02-14 |
재단법인 의약바이오컨버젼스연구단 |
신규한 아닐린 유도체 및 이의 용도
|
|
AR091790A1
(es)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
Derivados de isoquinolin-1-ona y sus usos
|
|
CA2864356A1
(en)
*
|
2012-02-10 |
2013-08-15 |
The Board Of Regents Of The University Of Texas System |
Modulators of exchange proteins directly activated by camp (epacs)
|
|
US9051299B2
(en)
|
2012-03-29 |
2015-06-09 |
Merck Sharp & Dohme Corp. |
Imidazolyl methyl piperidine T-type calcium channel antagonists
|
|
WO2013166037A1
(en)
|
2012-05-01 |
2013-11-07 |
The Trustees Of Columbia University In The City Of New York |
Non-retinoid antagonists for treatment of eye disorders
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
CN103570705B
(zh)
*
|
2012-07-18 |
2017-01-25 |
中国医学科学院医药生物技术研究所 |
取代的n‑((1＇,3＇‑杂唑‑4＇‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途
|
|
EP2892880B1
(en)
|
2012-09-07 |
2017-11-22 |
Novartis AG |
Indole carboxamide derivatives and uses thereof
|
|
BR102012024778A2
(pt)
*
|
2012-09-28 |
2014-08-19 |
Cristalia Prod Quimicos Farm |
Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
|
|
KR102229478B1
(ko)
|
2012-11-01 |
2021-03-18 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
|
|
CN104936963B
(zh)
*
|
2012-11-20 |
2017-11-28 |
普罗齐纳斯有限公司 |
作为蛋白激酶抑制剂的硫醚衍生物
|
|
EP2733146A1
(en)
*
|
2012-11-20 |
2014-05-21 |
KTB Tumorforschungsgesellschaft mbH |
Thioether derivatives as protein kinase inhibitors
|
|
US9296755B2
(en)
|
2013-01-25 |
2016-03-29 |
Glaxosmithkline Intellectual Property Development Limited |
3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
|
|
US9745328B2
(en)
|
2013-02-04 |
2017-08-29 |
Janssen Pharmaceutica Nv |
Flap modulators
|
|
TWI644899B
(zh)
|
2013-02-04 |
2018-12-21 |
健生藥品公司 |
Ｆｌａｐ調節劑
|
|
WO2014151936A1
(en)
|
2013-03-14 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Octahydropyrrolopyrroles, their preparation and use
|
|
US9938291B2
(en)
|
2013-03-14 |
2018-04-10 |
The Trustess Of Columbia University In The City Of New York |
N-alkyl-2-phenoxyethanamines, their preparation and use
|
|
EP2968304B1
(en)
|
2013-03-14 |
2018-10-10 |
The Trustees of Columbia University in the City of New York |
4-phenylpiperidines, their preparation and use
|
|
ES2700541T3
(es)
|
2013-03-14 |
2019-02-18 |
Univ Columbia |
Octahidrociclopentapirroles, su preparación y uso
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
WO2015039333A1
(en)
|
2013-09-22 |
2015-03-26 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
JP6498672B2
(ja)
*
|
2013-12-20 |
2019-04-10 |
エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. |
疼痛に対して多重モードの活性を有するピペリジン化合物
|
|
ES2796090T3
(es)
|
2014-02-10 |
2020-11-25 |
Inst Curie |
Uso de moduladores MCOLN-1 para regular la migración celular
|
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2015168286A1
(en)
|
2014-04-30 |
2015-11-05 |
The Trustees Of Columbia University In The City Of New York |
Substituted 4-phenylpiperidines, their preparaiton and use
|
|
CA2998647A1
(en)
*
|
2014-10-03 |
2016-04-07 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
|
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
|
HRP20210320T1
(hr)
|
2014-10-24 |
2021-04-30 |
Takeda Pharmaceutical Company Limited |
Spojevi heteroarila za liječenje oftalmičkih bolesti
|
|
WO2016077793A1
(en)
*
|
2014-11-14 |
2016-05-19 |
Children's Hospital Medical Center |
Sos1 inhibitors for cancer treatment
|
|
SI3321265T1
(sl)
|
2015-03-04 |
2020-07-31 |
Gilead Sciences, Inc. |
Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
|
|
US9737512B2
(en)
|
2015-03-11 |
2017-08-22 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions for treating chronic pain
|
|
US10421756B2
(en)
|
2015-07-06 |
2019-09-24 |
Rodin Therapeutics, Inc. |
Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
|
|
RS62639B1
(sr)
|
2015-07-06 |
2021-12-31 |
Alkermes Inc |
Hetero-halo inhibitori histonskih deacetilaza
|
|
MX389514B
(es)
|
2015-10-01 |
2025-03-20 |
Firmenich Incorporated |
Compuestos útiles como moduladores de canal receptor 8 de potencial transitorio de melastatina (trpm8).
|
|
EP3388420B1
(en)
*
|
2015-12-07 |
2022-06-22 |
Hinova Pharmaceuticals Inc. |
Quinoline compounds, preparation method thereof, and use thereof as urate transporter inhibitor drug
|
|
IL263680B2
(en)
|
2016-06-24 |
2025-10-01 |
Infinity Pharmaceuticals Inc |
PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
|
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
|
JP6746776B2
(ja)
|
2016-09-02 |
2020-08-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｏｌｌ様受容体調節剤化合物
|
|
CN106565643A
(zh)
*
|
2016-10-31 |
2017-04-19 |
北京大学 |
D‑3‑磷酸甘油酸脱氢酶别构抑制剂及其应用
|
|
US10722489B2
(en)
*
|
2016-10-31 |
2020-07-28 |
Peking University |
D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof
|
|
MD3570834T2
(ro)
|
2017-01-11 |
2022-04-30 |
Alkermes Inc |
Inhibitori biciclici ai histon deacetilazei
|
|
CN106822897B
(zh)
*
|
2017-02-17 |
2018-10-19 |
河北盛华尔生物医疗科技有限公司 |
靶向下调trpm7基因表达在提高肺鳞癌化疗敏感性方面的应用
|
|
CN110709394B
(zh)
*
|
2017-03-31 |
2025-02-21 |
中美博瑞纳制药有限公司 |
可用作alcat1抑制剂的化合物
|
|
WO2018232160A1
(en)
*
|
2017-06-15 |
2018-12-20 |
Belite Bio, Inc |
Methods of treating metabolic diseases with phenoxyethylamides
|
|
EP3638239A4
(en)
|
2017-06-15 |
2021-03-10 |
Belite Bio, Inc |
METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH RBP4 USING TRIAZOLOPYRIDINES
|
|
EP3638238A4
(en)
|
2017-06-15 |
2021-03-10 |
Belite Bio, Inc |
METHODS FOR TREATING METABOLIC DISEASES WITH FUSION BICYCLIC PYRAZOLES
|
|
JP7152471B2
(ja)
|
2017-08-07 |
2022-10-12 |
ロダン・セラピューティクス，インコーポレーテッド |
ヒストン脱アセチル化酵素の二環阻害剤
|
|
UY38525A
(es)
*
|
2018-12-21 |
2020-07-31 |
Bayer Ag |
1,3,4-oxadiazoles y derivados de éstos como nuevos agentes fungicidas
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
JP2022540818A
(ja)
|
2019-07-08 |
2022-09-20 |
ビーライト バイオ，エルエルシー |
Ｒｂｐ４阻害剤の製剤および使用の方法
|
|
EP4085056A1
(en)
|
2020-01-03 |
2022-11-09 |
Berg LLC |
Polycyclic amides as ube2k modulators for treating cancer
|
|
US11753413B2
(en)
|
2020-06-19 |
2023-09-12 |
Incyte Corporation |
Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
|
|
US11691971B2
(en)
|
2020-06-19 |
2023-07-04 |
Incyte Corporation |
Naphthyridinone compounds as JAK2 V617F inhibitors
|
|
WO2022006456A1
(en)
|
2020-07-02 |
2022-01-06 |
Incyte Corporation |
Tricyclic pyridone compounds as jak2 v617f inhibitors
|
|
RS66978B1
(sr)
|
2020-07-02 |
2025-07-31 |
Incyte Corp |
Triciklična jedinjenja uree kao inhibitori jak2 v617f
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
US20240002395A1
(en)
*
|
2020-12-04 |
2024-01-04 |
The Johns Hopkins University |
Compounds and their use for treating neuropathic pain
|
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
WO2022182839A1
(en)
|
2021-02-25 |
2022-09-01 |
Incyte Corporation |
Spirocyclic lactams as jak2 v617f inhibitors
|
|
US20240208956A1
(en)
*
|
2021-04-08 |
2024-06-27 |
Chong Kun Dang Pharmaceutical Corp. |
1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
|
|
CN114685371A
(zh)
*
|
2022-03-08 |
2022-07-01 |
四川大学 |
吡唑甲酰胺衍生物及其制备方法和用途
|
|
KR20240163688A
(ko)
|
2022-03-17 |
2024-11-19 |
인사이트 코포레이션 |
Jak2 v617f 억제제로서의 삼환계 우레아 화합물
|
|
WO2024059524A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Hotspot Therapeutics, Inc. |
Pyrazolylcarboxamide compounds and their use in therapy
|